Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.

ABSTRACT:

Background

The majority of current pharmacological treatments for Parkinson's disease (PD) were approved for clinical use in the second half of the last century and they only provide symptomatic relief. Derivatives of these therapies continue to be explored in clinical trials, together with potentially disease modifying therapies that can slow, stop or reverse the condition.

Objective

To provide an overview of the pharmacological therapies- both symptomatic and disease modifying- currently being clinically evaluated for PD, with the goal of creating greater awareness and opportunities for collaboration amongst commercial and academic researchers as well as between the research and patient communities.

Methods

We conducted a review of clinical trials of drug therapies

SUBMITTER: McFarthing K 

PROVIDER: S-EPMC7458531 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature